Oncology CRO: Oncology and Hematology Expertise
The search for answers can’t wait
Oncology and hematology studies dominate the clinical trial landscape, but the path to regulatory approval is complex and uncertain. And for the millions of patients each year facing a cancer diagnosis, the search for answers can’t wait.
While advancements in oncology and hematology clinical research bring hope to patients, they can present challenges to drug developers, including:
- Complexity of innovative trial designs and master protocols
- Enrollment barriers that hinder diversity and inclusion goals
- Intense competition for qualified sites and patients
- Higher data volume and collection requirements compared to other therapeutic areas
- Rapidly changing standards of care and clinical strategies
- Regulatory and payor requirements that necessitate long-term follow-up
To navigate these complexities, you need a nuanced clinical development strategy and the partnership of an experienced contract research organization (CRO) with patient-centric technologies and end-to-end solutions that span all phases of development.
With experience in more than 700 hematology and oncology clinical trials, the PPD clinical research business of Thermo Fisher Scientific has expertise across the full range of cancer therapies — from immuno-oncology and targeted therapies to novel and emerging therapies, including cell and gene therapies.
Learn more about managing complex clinical trials.
Accelerating hematology & oncology clinical research with proven experience
For the over 30 years, drug developers have partnered with the PPD clinical research team to develop and commercialize their hematology and oncology treatments. Success in hematology and oncology clinical research requires partners with a deep understanding of the disease and an unrelenting dedication to developing the solutions patients need. In the past five years alone, we have supported 34 oncology drug approvals in the U.S. — including three first-in-class products — and 25 EMEA approvals.
studies
patients
sites
countries
Advance your clinical research with a full spectrum of end-to-end oncology solutions
As the clinical research business of Thermo Fisher Scientific, PPD provides support in all phases of oncology development — from early drug discovery support and clinical development to market access and commercial strategy — with innovative technologies and solutions. Our dedicated teams are equipped with the knowledge, experience, and solutions to reduce patient burden and make trial participation viable for patients while achieving optimal doses, accelerating timelines and maximizing cost savings.
With a full spectrum of end-to-end solutions, we enable drug developers of all sizes to:
- Leverage adaptive trial designs that take advantage of innovative approaches in data collection and statistical assessments
- Flex midstream by altering control arms or expanding the number of arms in response to early findings
- Enrich the patient population using biomarker-driven randomization to target subjects most likely to respond
- Select an appropriate country mix based on the phase of clinical development, patient population, competition, regional and national standards of care, regulatory environment, and protocol complexities
By partnering with us, you gain access to the latest oncology technologies, world-class laboratories, contract development and manufacturing organization (CDMO) services, and peri- and post-approval services.
Explore our end-to-end oncology capabilities
Next-generation sequencing
The search for answer requires transformative technology that advances. Oncomine™ Solutions — the latest technology for fast-profiling and next-generation sequencing of key biomarkers and comprehensive genomic profiling — provides molecular insights to inform the most critical decisions with speed and accuracy.
